- Novavax (NVAX) jumps 9% premarket.
- Wednesday evening, the company announced that The New England Journal of Medicine published what NVAX calls "positive clinical data" from a study of the VLP A(H7N9) vaccine candidate.
- Summary: The vaccine was well tolerated, safety was "in-line with previous findings," and 81% and 97% of 5ug adjuvanted vaccine recipients had protective HAI levels and anti-neuraminidase antibody responses, respectively. (PR)
Novavax rises on publication of data from A(H7N9) vaccine candidate study
Nov 14 2013, 09:05 ET